All In Biotech

Drug Trial Radar · NCT02960711

Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome

Randomized Controlled Trial of Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome

Last checked: Nov 19, 2026Latest source record: Sep 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,600 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,600

Actual

Start

Feb 2014

Primary completion

Jul 2019

Study completion Jul 2019

Sponsor

Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 55 years, up to 74 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase III randomized controlled trial on men and women with Metabolic syndrome (MetS) to test the hypothesis that comprehensive life-style changes and/or metformin treatment prevent age-related chronic non-communicable diseases (ArCD). The aim of the present study is to evaluate the effect of a comprehensive life-style intervention (including moderate physical activity and Mediterranean/macrobiotic diet with moderate calorie and protein restriction), and of treatment with Metformin (a calorie restriction mimetic drug) for the prevention of ArCD.

Conditions

  • Metabolic Syndrome

Interventions

  • Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]Drug

  • Ludipress, mg stereate, micronized hydrated silica, talcumDrug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total incidence of age related chronic diseasesTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fondazione IRCCS Istituto Nazionale Tumori

    Milan, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.